Mariner
GLUE icon

Mariner’s Monte Rosa Therapeutics GLUE Stock Holding History

Mariner’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,117
Closed -$282K – 3685
2026
Q1 		$282K Sell
17,117
-4,483
-21% -$85.7K ﹤0.01% 2929
2025
Q4 		$340K Buy
21,600
+7,837
+57% +$106K ﹤0.01% 2738
2025
Q3 		$102K Sell
13,763
-1,096
-7% -$5.8K ﹤0.01% 3352
2025
Q2 		$67K Buy
+14,859
New +$66.3K ﹤0.01% 3301

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mariner's GLUE Position: Q2 2026 in Review

Mariner sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 17,117 shares — an estimated $282K sold.

Mariner first reported a position in GLUE in Q2 2025 and held it in 4 quarters. The position peaked at $340K in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Mariner reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 17,117 Monte Rosa Therapeutics shares in Q2 2026, an estimated $282K.
  • Mariner first reported a position in Monte Rosa Therapeutics in Q2 2025 and held it in 4 quarters.
  • Mariner's Monte Rosa Therapeutics position peaked at $340K in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.